Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy

M. Janice Lu, Joan Sorich, Maitreyee Hazarika, Mimi Kim, Giuseppe Del Priore, Allan J. Jacobs, Chang Chiang, Paul C. Liu, Eileen Fusco, John P. Curtin, Franco M. Muggia

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Abstract

Although three large phase III trials have documented the benefit of IP chemotherapy, this therapy as consolidation has been studied in only a few pilot studies. These small studies have included patients with a variety of baseline prognostic characteristics, and only one series had a comparator group of surgically documented pathologic complete response to uniform systemic chemotherapy. No randomized trials have been done to assess the impact of IP consolidation on progression-free survival or survival in either positively or negatively reassessed patients. It is hoped that the current experience will trigger further consideration of future phase III trials to assess the value of IP consolidation after initial induction with chemotherapy (ie, chemical debulking).

Original languageEnglish (US)
Pages (from-to)969-975
Number of pages7
JournalHematology/Oncology Clinics of North America
Volume17
Issue number4
DOIs
StatePublished - Aug 2003
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy'. Together they form a unique fingerprint.

Cite this